Breaking News Instant updates and real-time market news.

EXEL

Exelixis

$28.00

0.14 (0.50%)

, RHHBY

Roche

$30.69

0.18 (0.59%)

15:22
01/20/18
01/20
15:22
01/20/18
15:22

Exelixis presents updated results from Phase 1b clinical trial in CRC

Exelixis (EXEL) announced the presentation of updated results from the Genentech-sponsored phase 1b clinical trial of cobimetinib, an Exelixis-discovered MEK inhibitor, in combination with atezolizumab, an anti-PDL1 antibody discovered and developed by Genentech, a member of the Roche Group (RHHBY), in patients with metastatic colorectal cancer. "The results of this study suggest the combination of cobimetinib and atezolizumab continues to be associated with encouraging tolerability and clinical activity in patients with metastatic colorectal cancer," said Michael Morrissey, President and Chief Executive Officer of Exelixis. "In addition, the combination demonstrated a median 13-month overall survival as well as durable responses in patients with microsatellite-stable tumors, which have historically been resistant to immunotherapy administered on its own. We look forward to the readout of IMblaze370, the ongoing confirmatory phase 3 pivotal trial evaluating the combination of cobimetinib and atezolizumab in the third-line treatment setting, anticipated in the first half of this year." The ongoing phase 1b trial evaluates the combination of cobimetinib and atezolizumab in a variety of solid tumors. Following the selection of a recommended dose in the trial's dose escalation stage, expansion cohorts in metastatic CRC, non-small cell lung cancer, and melanoma began enrolling. The trial's primary endpoints are the evaluation of the safety and tolerability of the combination. Secondary endpoints include investigator-assessed objective response rate, progression-free survival by RECIST 1.1, and overall survival.

EXEL

Exelixis

$28.00

0.14 (0.50%)

RHHBY

Roche

$30.69

0.18 (0.59%)

  • 25

    Jan

  • 01

    Feb

  • 08

    Feb

  • 15

    Feb

  • 23

    Feb

EXEL Exelixis
$28.00

0.14 (0.50%)

10/16/17
RHCO
10/16/17
NO CHANGE
Target $35
RHCO
Buy
Cabo result better positions Exelixis as acquisition target, says SunTrust
SunTrust analyst Peter Lawson raised his price target on Exelixis (EXEL) to $35 from $33 and maintained his Buy rating, saying the latest CELESTIAL trial cabozantinib positions the treatment well against its main competitor - Bayer's (BAYRY) Regorafenib. Lawson adds that the trial result validates the expansion of cabozantinib beyond kidney cancer and better positions Exelixis as a potentially attractive M&A target.
10/16/17
PIPR
10/16/17
NO CHANGE
Target $33
PIPR
Overweight
Exelixis price target raised to $33 from $29 at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff raised his price target for Exelixis shares to $33 after the company said the Phase III Celestial trial of Cabometyx met the primary endpoint. The analyst is confident front-line approval next year will grow renal cell carcinoma product sales to $392M in 2018. He reiterates an Overweight rating on Exelixis.
10/17/17
NEED
10/17/17
NO CHANGE
Target $33
NEED
Buy
Exelixis price target raised to $33 from $30 at Needham
Needham analyst Chad Messer raised his price target on Exelixis (EXEL) to $33, noting the latest trial data for advanced renal cell carcinoma treatment, Cabozantinib, positions it for near and long term growth. Messer says the results may be sufficient to allay competitive concerns from the recently approved Bayer (BAYRY) Stivarga, as cabozantinib offers a potentially more attractive efficacy profile.
01/04/18
PIPR
01/04/18
NO CHANGE
Target $37
PIPR
Overweight
Piper ups Exelixis target to $37, names a top pick for 2018
Piper Jaffray analyst Edward Tenthoff names Exelixis a top pick for 2018 and raised his price target for the shares to $37 from $33. The analyst expects Cabometyx growth from driven label expansion and is positive into the Phase III Cotexo data in the first half of 2018.
RHHBY Roche
$30.69

0.18 (0.59%)

12/26/17
12/26/17
NO CHANGE

On The Fly: Top five analyst actions
Catch up on today's top five analyst rating changes with this list compiled by The Fly: 1. Raymond James analyst Budd Bugatch upgraded Herman Miller (MLHR) to Outperform following newly passed tax reform, as the analyst believes the economic backdrop favors a strong office furniture demand environment and tax reform increases incentives for office furniture purchases. 2. Bugatch also upgraded Knoll (KNL) following the enactment of U.S. tax reform, as he believes its sales force, new product offerings, competitive pricing, and recently announced Muuto acquisition position the company to drive revenue growth as macro conditions improve. 3. Janney Capital analyst Michael Gaugler upgraded Unitil (UTL) to Buy citing the stock's "compelling" valuation. 4. William Blair analyst Tim Lugo late Friday downgraded Agile Therapeutics (AGRX) to Market Perform from Outperform after the company received a complete response letter from the FDA over its hormonal contraceptive patch, Twirla. While the issues raised by the FDA may be addressable, he has concerns regarding management's execution of the company's lead product. 5. Ignyta (RXDX) was downgraded to Hold at SunTrust and to Neutral at Ladenburg after the company agreed to be acquired by Roche (RHHBY) for $27 per share. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
12/28/17
CANT
12/28/17
DOWNGRADE
Target $27
CANT
Neutral
Ignyta downgraded to Neutral from Overweight at Cantor Fitzgerald
Cantor Fitzgerald analyst Mara Goldstein downgraded Ignyta (RXDX) to Neutral saying a competing takeover bid to Roche's (RHHBY) is unlikely. The analyst raised her price target for the shares to $27 from $23.
12/29/17
JPMS
12/29/17
NO CHANGE
JPMS
Roche added to Analyst Focus List at JPMorgan
JPMorgan analyst Richard Vosser added Roche (RHHBY) to his firm's Analyst Focus List and keeps an Overweight rating on the shares with a SFR 300 price target. The analyst sees Roche as having the most significant earnings upside potential of any of the European large cap pharma stocks in 2018. He believes the potential of the company's pipeline is being underappreciated at current share levels. His top picks for 2018 are Roche and Bayer (BAYRY).
01/15/18
SOCG
01/15/18
DOWNGRADE
SOCG
Sell
Roche downgraded to Sell from Hold at Societe Generale
Societe Generale analyst Justin Smith downgraded Roche to Sell and cut his price target for the shares to CHF 190 from CHF 250.The analyst sees downside risk to consensus estimates from generic competition and expects the stock to underperform.

TODAY'S FREE FLY STORIES

AMZN

Amazon.com

$1,844.00

21.98 (1.21%)

08:32
07/18/18
07/18
08:32
07/18/18
08:32
Hot Stocks
GrowGeneration forms strategic partnership with Amazon.com »

GrowGeneration announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

  • 26

    Jul

  • 16

    Aug

PYPL

PayPal

$88.59

0.82 (0.93%)

, AMZN

Amazon.com

$1,844.00

21.98 (1.21%)

08:32
07/18/18
07/18
08:32
07/18/18
08:32
Recommendations
PayPal, Amazon.com, GrubHub analyst commentary  »

PayPal price target…

PYPL

PayPal

$88.59

0.82 (0.93%)

AMZN

Amazon.com

$1,844.00

21.98 (1.21%)

GRUB

GrubHub

$113.93

3.76 (3.41%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

  • 25

    Jul

  • 26

    Jul

  • 15

    Aug

  • 16

    Aug

  • 16

    Aug

  • 17

    Sep

  • 18

    Sep

BWP

Boardwalk Pipeline

$0.00

(0.00%)

08:30
07/18/18
07/18
08:30
07/18/18
08:30
Options
One option delisting on July 18th »

Option delistings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HCSG

Healthcare Services

$42.38

-0.3297 (-0.77%)

, GEN

Genesis Healthcare

$1.45

-0.09 (-5.84%)

08:27
07/18/18
07/18
08:27
07/18/18
08:27
Recommendations
Healthcare Services, Genesis Healthcare analyst commentary  »

Benchmark would be buyers…

HCSG

Healthcare Services

$42.38

-0.3297 (-0.77%)

GEN

Genesis Healthcare

$1.45

-0.09 (-5.84%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

  • 05

    Oct

FPI

Farmland Partners

$6.28

0.185 (3.04%)

08:26
07/18/18
07/18
08:26
07/18/18
08:26
Upgrade
Farmland Partners rating change  »

Farmland Partners…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ERIC

Ericsson

$7.64

-0.015 (-0.20%)

08:25
07/18/18
07/18
08:25
07/18/18
08:25
Earnings
Ericsson reports Q2 non-IFRS EPS SEK(9) vs. SEK33 last year »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GLOG

GasLog

$17.10

(0.00%)

, GLNG

Golar LNG

$27.06

0.11 (0.41%)

08:23
07/18/18
07/18
08:23
07/18/18
08:23
Initiation
GasLog, Golar LNG, GasLog Partners, Golar LNG Partners, Hoegh LNG initiated  »

GasLog, GolarLNG…

GLOG

GasLog

$17.10

(0.00%)

GLNG

Golar LNG

$27.06

0.11 (0.41%)

GLOP

GasLog Partners

$23.40

0.05 (0.21%)

GMLP

Golar LNG Partners

$14.71

-0.09 (-0.61%)

HMLP

Hoegh LNG

$17.90

0.3 (1.70%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

  • 01

    Oct

CMA

Comerica

$91.84

1.15 (1.27%)

, BBT

BB&T

$51.99

0.37 (0.72%)

08:22
07/18/18
07/18
08:22
07/18/18
08:22
Recommendations
Comerica, BB&T, U.S. Bancorp analyst commentary  »

Comerica could be viewed…

CMA

Comerica

$91.84

1.15 (1.27%)

BBT

BB&T

$51.99

0.37 (0.72%)

USB

U.S. Bancorp

$51.29

-0.01 (-0.02%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

  • 19

    Jul

$DJT

DJ Transportation Average

$0.00

(0.00%)

08:20
07/18/18
07/18
08:20
07/18/18
08:20
Technical Analysis
DJ Transportation Average: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$DJU

DJ Utility Average

$0.00

(0.00%)

08:20
07/18/18
07/18
08:20
07/18/18
08:20
Technical Analysis
DJ Utility Average: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DJX

Dow Jones Industrial Average

$0.00

(0.00%)

08:20
07/18/18
07/18
08:20
07/18/18
08:20
Technical Analysis
Dow Jones Industrial Average: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KDP

Keurig Dr Pepper

$24.97

0.2 (0.81%)

08:20
07/18/18
07/18
08:20
07/18/18
08:20
Initiation
Keurig Dr Pepper initiated  »

Keurig Dr Pepper…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IYT

iShares Transportation Average

$188.40

0.48 (0.26%)

08:20
07/18/18
07/18
08:20
07/18/18
08:20
Technical Analysis
iShares Transportation Average: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLK

Technology Select Sector SPDR

$72.90

0.54 (0.75%)

08:19
07/18/18
07/18
08:19
07/18/18
08:19
Technical Analysis
Technology Select Sector SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLE

Energy Select Sector SPDR

$75.10

-0.26 (-0.35%)

08:19
07/18/18
07/18
08:19
07/18/18
08:19
Technical Analysis
Energy Select Sector SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLY

Consumer Discretionary Sector SPDR

$112.97

0.12 (0.11%)

08:19
07/18/18
07/18
08:19
07/18/18
08:19
Technical Analysis
Consumer Discretionary Sector SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLB

S&P Select Materials SPDR

$58.88

0.76 (1.31%)

08:19
07/18/18
07/18
08:19
07/18/18
08:19
Technical Analysis
S&P Select Materials SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLU

Utilities SPDR

$52.45

-0.03 (-0.06%)

08:18
07/18/18
07/18
08:18
07/18/18
08:18
Technical Analysis
Utilities SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLP

Consumer Staples Sector SPDR

$52.92

0.44 (0.84%)

08:18
07/18/18
07/18
08:18
07/18/18
08:18
Technical Analysis
Consumer Staples Sector SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLV

Health Care Select Sector SPDR

$87.34

0.49 (0.56%)

08:18
07/18/18
07/18
08:18
07/18/18
08:18
Technical Analysis
Health Care Select Sector SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IWM

iShares Trust Russell 2000 Index Fund

$167.51

0.75 (0.45%)

08:17
07/18/18
07/18
08:17
07/18/18
08:17
Technical Analysis
iShares Trust Russell 2000 Index Fund: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DIA

Diamonds Fund ETF

$251.26

0.64 (0.26%)

08:17
07/18/18
07/18
08:17
07/18/18
08:17
Technical Analysis
Diamonds Fund ETF: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPY

SPDR S&P 500 ETF Trust

$280.42

1.04 (0.37%)

08:17
07/18/18
07/18
08:17
07/18/18
08:17
Technical Analysis
SPDR S&P 500 ETF Trust: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLF

Financial Select Sector

$27.49

0.04 (0.15%)

08:17
07/18/18
07/18
08:17
07/18/18
08:17
Technical Analysis
Financial Select Sector: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SMH

Market Vectors Semiconductor

$106.04

1.39 (1.33%)

08:16
07/18/18
07/18
08:16
07/18/18
08:16
Technical Analysis
Market Vectors Semiconductor: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.